Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

VBI-1901

Generic Name: VBI-1901

Drug Type: Biotech

Overview

VBI-1901 is a bivalent cytomeglaovirus gB/pp65 enveloped virus-like particles

Background

VBI-1901 is a bivalent cytomeglaovirus gB/pp65 enveloped virus-like particles

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Phase 1

Recruiting

Posted: 2017/12/26

Sponsor:VBI Vaccines Inc.

ID:NCT03382977

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Brain Hemorrhage Treatment Market Expected to Grow Significantly by 2032 as AI Solutions Gain FDA Approval

2 months ago

The brain hemorrhage treatment market is projected to experience substantial growth through 2032, driven by an aging population and increasing prevalence of risk factors such as hypertension and traumatic brain injuries.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy